MYRIAD GENETICS, INC. (MYGN)

Every figure this model derived for MYGN, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 15,000,000 PaymentsToAcquireOtherProductiveAssets 2026-06-30
cash 115,200,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 289,000,000 AssetsCurrent 2026-06-30
current liabilities 130,700,000 LiabilitiesCurrent 2026-06-30
equity 303,900,000 StockholdersEquity 2026-06-30
interest expense 16,400,000 InterestExpenseNonoperating 2026-06-30
ocf 7,700,000 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 806,600,000 RevenueFromContractWithCustomerExcludingAssessedTax 2026-06-30
sbc 28,700,000 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up MYGN on one particular measure came for.

RatioValue
cash operating margin-2.44
current ratio2.21
current ratio reported2.21
deferred revenue growth-16.67
dilution pct2.21
fcf margin-0.91
growth cv1.12
interest cover-6.01
operating margin-12.22
owner earnings margin-4.46
revenue growth-3.16
revenue growth per share-5.25
roic-25.18
rpo growth148.15
rule of 40-15.38
sbc pct revenue3.56

What to be careful about

What this model itself distrusts about MYGN's figures. Written by the derivation as it ran, not added afterwards.